Celldex Therapeutics Inc. (NASDAQ:CLDX) and Regulus Therapeutics Inc. (NASDAQ:RGLS) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics Inc.	11.23M	8.74	145.62M	-1.16	0.00
Regulus Therapeutics Inc.	N/A	111.81	54.59M	-2.11	0.00

Demonstrates Celldex Therapeutics Inc. and Regulus Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both businesses.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics Inc.	-1,296.71%	-93%	-68.2%
Regulus Therapeutics Inc.	0.00%	-311.5%	-97.6%

Volatility & Risk

Celldex Therapeutics Inc.’s current beta is 2.61 and it happens to be 161.00% more volatile than Standard and Poor’s 500. Regulus Therapeutics Inc.’s 74.00% more volatile than Standard and Poor’s 500 which is a result of the 1.74 beta.

Liquidity

The Current Ratio of Celldex Therapeutics Inc. is 6.6 while its Quick Ratio stands at 6.6. The Current Ratio of rival Regulus Therapeutics Inc. is 1 and its Quick Ratio is has 1. Celldex Therapeutics Inc. is better equipped to clear short and long-term obligations than Regulus Therapeutics Inc.

Insider and Institutional Ownership

Roughly 29.4% of Celldex Therapeutics Inc. shares are held by institutional investors while 36.5% of Regulus Therapeutics Inc. are owned by institutional investors. Insiders held 0.2% of Celldex Therapeutics Inc. shares. Comparatively, insiders own roughly 9% of Regulus Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Celldex Therapeutics Inc.	-7.6%	-18.11%	-35.84%	-58.49%	-90.58%	-90.29%
Regulus Therapeutics Inc.	-8.7%	-17.42%	-42.38%	-82.5%	-86.23%	-88.22%

For the past year Celldex Therapeutics Inc.’s stock price has bigger decline than Regulus Therapeutics Inc.

Summary

Celldex Therapeutics Inc. beats on 5 of the 9 factors Regulus Therapeutics Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.